Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (41-50 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|June 5, 1999
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implicationsS Haas, J M Walenga, W P Jeske, et al.
The Medical Clinics of North America|May 1, 1994
Current trends in the development of anticoagulant and antithrombotic drugsJ Fareed, D Hoppensteadt, J M Walenga, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1986
In vitro evaluation of heparin fractions: old vs. new methodsJ M Walenga, J Fareed, D Hoppensteadt, et al.
Haemostasis|January 1, 1991
Recombinant hirudin--initial observations in reconstructive microsurgeryK Narayanan, J M Walenga, M D Liang, et al.
Seminars in Thrombosis and Hemostasis|July 1, 1989
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerationsJ M Walenga, R Pifarre, D A Hoppensteadt, et al.
Perfusion|May 4, 2001
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management testM Wallock, W P Jeske, M Bakhos, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 10, 1998
Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gammaD J Dries, J M Walenga, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1984
Performance characteristics of a simple radioimmunoassay for fibrinopeptide AJ M Walenga, D Hoppensteadt, R M Emanuele, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitorsS Haas, J M Walenga, W P Jeske, et al.
Expert Opinion on Investigational Drugs|July 5, 2005
Pharmacology of argatrobanW Jeske, J M Walenga, B E Lewis, et al.
Pageof 20

Showing results (41-50 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|June 5, 1999
Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implicationsS Haas, J M Walenga, W P Jeske, et al.
The Medical Clinics of North America|May 1, 1994
Current trends in the development of anticoagulant and antithrombotic drugsJ Fareed, D Hoppensteadt, J M Walenga, et al.
Critical Reviews in Clinical Laboratory Sciences|January 1, 1986
In vitro evaluation of heparin fractions: old vs. new methodsJ M Walenga, J Fareed, D Hoppensteadt, et al.
Haemostasis|January 1, 1991
Recombinant hirudin--initial observations in reconstructive microsurgeryK Narayanan, J M Walenga, M D Liang, et al.
Seminars in Thrombosis and Hemostasis|July 1, 1989
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerationsJ M Walenga, R Pifarre, D A Hoppensteadt, et al.
Perfusion|May 4, 2001
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management testM Wallock, W P Jeske, M Bakhos, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 10, 1998
Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gammaD J Dries, J M Walenga, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1984
Performance characteristics of a simple radioimmunoassay for fibrinopeptide AJ M Walenga, D Hoppensteadt, R M Emanuele, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitorsS Haas, J M Walenga, W P Jeske, et al.
Expert Opinion on Investigational Drugs|July 5, 2005
Pharmacology of argatrobanW Jeske, J M Walenga, B E Lewis, et al.
Pageof 20